Analyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab
In this real-world cohort, infectious complications emerged early and frequently during teclistamab therapy and were a major driver of treatment interruption and permanent discontinuation. The clinical impact of infection extended beyond acute morbidity, often limiting continued access to an otherwise effective therapy in a heavily pretreated population. These findings highlight the need for proactive, individualized infection risk assessment and for standardized, evidence-informed approaches to infection monitoring, prophylaxis, and treatment modification during teclistamab therapy. Larger, multicenter studies will be essential to define strategies that balance infection risk with treatment durability in patients with limited therapeutic alternatives.
Authors
- Kevin Rakszawski (ORCID: https://orcid.org/0000-0001-7441-9531)
- Manpreet Sandhu
- Yoshitaka Inoue (ORCID: https://orcid.org/0000-0002-3967-7356)
- Kentaro Minagawa (ORCID: https://orcid.org/0000-0003-1740-7109)
- Charyguly Annageldiyev (ORCID: https://orcid.org/0000-0003-0293-7203)
- Emma Guare
- Paddy Ssentongo (ORCID: https://orcid.org/0000-0003-1565-5731)
- Catharine I. Paules (ORCID: https://orcid.org/0000-0002-9064-6678)
- Chen Song (ORCID: https://orcid.org/0009-0001-6450-393X)
- Seema Naik
- Jeffrey Sivik
- Shin Mineishi
Institutions
- Pennsylvania State University (US)
- Penn State Milton S. Hershey Medical Center (US)
Publication Details
- Journal
- Current Oncology
- Published
- 2026-03-08
- DOI
- https://doi.org/10.3390/curroncol33030154
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Pennsylvania
- Pennsylvania State University
- Penn State Hershey Cancer Institute